Janux Therapeutics (JANX) Return on Sales (2021 - 2025)
Historic Return on Sales for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 2.43%.
- Janux Therapeutics' Return on Sales rose 614800.0% to 2.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.19%, marking a year-over-year decrease of 55500.0%. This contributed to the annual value of 6.52% for FY2024, which is 7000.0% up from last year.
- Per Janux Therapeutics' latest filing, its Return on Sales stood at 2.43% for Q3 2025, which was up 614800.0% from 240.64% recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Return on Sales registered a high of 0.67% during Q2 2024, and its lowest value of 240.64% during Q2 2025.
- Over the past 5 years, Janux Therapeutics' median Return on Sales value was 8.33% (recorded in 2025), while the average stood at 22.93%.
- Over the last 5 years, Janux Therapeutics' Return on Sales had its largest YoY gain of 614800bps in 2025, and its largest YoY loss of -2399700bps in 2025.
- Quarter analysis of 5 years shows Janux Therapeutics' Return on Sales stood at 8.3% in 2021, then soared by 32bps to 5.65% in 2022, then rose by 15bps to 4.78% in 2023, then tumbled by -36bps to 6.52% in 2024, then surged by 63bps to 2.43% in 2025.
- Its last three reported values are 2.43% in Q3 2025, 240.64% for Q2 2025, and 8.33% during Q1 2025.